AKAN
AKAN
NASDAQ · Pharmaceuticals

Akanda Corp

$3.11
-0.12 (-3.72%)
As of Sep 23, 11:04 PM ET ·
Financial Highlights (FY 2026)
Revenue
2.87M
Net Income
-508,163,820
Gross Margin
-60.4%
Profit Margin
-17,689.8%
Rev Growth
-53.8%
D/E Ratio
0.08
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin -60.4% -60.4% 35.1% 35.1%
Operating Margin -18,688.2% -16,819.4% 19.5% 18.5%
Profit Margin -17,689.8% -16,805.4% 13.3% 12.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 2.87M 6.22M 707.3K 858.5K
Gross Profit -1,736,483 -3,760,249 247.9K 300.9K
Operating Income -536,836,873 -1,046,239,033 138.2K 159.0K
Net Income -508,163,820 -990,358,245 94.3K 103.5K
Gross Margin -60.4% -60.4% 35.1% 35.1%
Operating Margin -18,688.2% -16,819.4% 19.5% 18.5%
Profit Margin -17,689.8% -16,805.4% 13.3% 12.1%
Rev Growth -53.8% -53.8% +7.8% +11.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 94.2K 94.2K 606.2K 721.3K
Total Equity 1.14M 1.14M 1.23M 1.39M
D/E Ratio 0.08 0.08 0.49 0.52
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -532,016,148 -1,094,446,385 212.4K 232.8K
Free Cash Flow 76.9K 86.9K